4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Rheumatoid Arthritis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 986 ongoing clinical trials involving Rheumatoid Arthritis
Of the 986 trials,256 trials are in Phase IV
Furthermore, 253 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Rheumatoid Arthritis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Rheumatoid Arthritis, an immunology condition. The largest number of ongoing clinical trials for Rheumatoid Arthritis is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Rheumatoid Arthritis-related drug trials.

Pfizer Inc: The leading ongoing Rheumatoid Arthritis related clinical trial sponsor

Pfizer Inc is the top sponsor for Rheumatoid Arthritis-related ongoing clinical trials.

Yunnan Provincial Traditional Chinese Medicine Hospital, Bristol-Myers Squibb Co, Eli Lilly and Co, and Johnson & Johnson are among other notable clinical trial sponsors involved in Rheumatoid Arthritis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Rheumatoid Arthritis

Upadacitinib (Rinvoq, Rim-Voq), Denosumab (Prolia, Pralia), and Etanercept (Enbrel, Enbrel PFS) are among the key marketed drugs involving Rheumatoid Arthritis.

Upadacitinib (Rinvoq, Rim-Voq) is an antineoplastic drug, acts as immunosuppressive agent. It functions via Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Inhibitor mechanism of action. It is formulated as extended-release tablets, extended-release coated tablets and extended-release film coated tablets for oral route of administration. Upadacitinib is marketed for the treatment of Rheumatoid Arthritis and several other indications including Ankylosing Spondylitis (Bekhterev's Disease), Psoriatic Arthritis, and Atopic Dermatitis (Atopic Eczema). Upadacitinib was first approved in 2019 and is marketed globally including the US, the UK, France, Canada, and Japan by AbbVie Inc.

Denosumab (Prolia, Pralia), is a human IgG2 monoclonal antibody. It functions via Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11) Inhibitor mechanism of action. It is formulated as solution for subcutaneous route of administration. Prolia is indicated for the treatment of Postmenopausal osteoporosis, fractures, bone loss in patients undergoing hormone ablation for cancer, pediatric glucocorticoid induced osteoporosis and pediatric osteogenesis imperfecta. Pralia also indicated for inhibition of the progression of bone erosion associated with rheumatoid arthritis. Denosumab was first approved in 2010 and is marketed globally including the US, the UK, France, Canada, and Japan by several pharma giants including Daiichi Sankyo Co Ltd, and Amgen Inc.